Table 2

Patients’ characteristics by treatment group

VariableControl* (N=88)Only HCQ (N=36)Only azithromycin (N=237)Azithromycin+HCQ (N=289)Azithromycin+oseltamivir (N=137)
Number%Number%Number%Number%Number%
Age
 <506068.182980.5616870.8916356.405842.34
 ≥502831.82719.446929.1112643.607957.66
Median (IQR)41.5 (31)29 (17.5)38 (23)48 (28)50 (26)
Sex
 Male4045.45513.8912653.1614550.175842.34
 Female4854.553186.1111146.8414449.837957.66
Presence of symptoms at the time of presentation
 No1820.451027.783615.19103.4621.46
 Yes7079.552672.2220184.8127996.5413598.54
Comorbid conditions
 No88100.002569.4423699.5820169.559770.80
 Yes00.001130.5610.428830.454029.20
Types of comorbid conditions
 Diabetes only00.0038.3300.00206.9242.92
 Hypertension only00.0012.7800.00165.5442.92
 Diabetes+hypertension00.0038.3300.00206.92128.76
SARI conditions†
 No8798.863083.3317272.5720771.639367.88
 Yes11.14616.676527.438228.374432.12
Respiratory support
 None88100.0036100.0000.0023480.977856.93
 Oxygen by mask/cannula00.0000.0000.005519.035943.07
 Non-invasive ventilation00.0000.0000.0000.0000.00
 Ventilator support00.0000.0000.0000.0000.00
Death‡33.4112.78135.4911840.8310576.64
  • *Patients with COVID-19 who received neither HCQ or azithromycin or oseltamivir or steroids independently or in combination.

  • †Respiratory rate >30 breaths/min, severe respiratory distress, SpO2 <90% on room air.

  • ‡Seventeen deceased individuals received only steroid/in combination with other drugs.

  • HCQ, hydroxychloroquine; SARI, severe acute respiratory infection.